BioIVT Highlights Advances in Assessing a Drug Candidate’s Risk of Producing Liver Damage at the Society of Toxicology Annual Meeting and ToxExpo

BioIVT will present a workshop and two poster sessions, and also exhibit at this year’s conference   

Westbury, NY – BioIVT, a leading provider of biospecimens and related services, today announced that it will be making several scientific contributions to the Society of Toxicology (SOT) 57th Annual Meeting and ToxExpo. This event will be held from Mar. 11-15 at the Henry B. González Convention Center in San Antonio, Texas.

“BioIVT is always looking for new ways to help researchers identify a drug candidate’s risk of producing drug-induced liver injury (DILI) earlier in the drug development process. At this year’s SOT conference, we will focusing on advances made using our C-DILI™ Assay and B-CLEAR® Technology,” said Dr. Christopher Black, senior vice president of ADME-Tox at BioIVT. “We look forward to sharing this newfound knowledge with our peers and helping to progress the field.”

BioIVT will be contributing to the following sessions:


Monday, Mar. 12
9:15 a.m. to 12:00 p.m.

  • Predicting Drug-Induced Cholestatic Injury in Humans

BioIVT Vice President, ADME-Tox Dr. Kenneth Brouwer will discuss how the C-DILI Assay, a novel in vitro method for predicting a compound’s potential for cholestatic drug-induced liver injury, can be used for lead selection and managing toxicity risk.


Thursday, Mar. 15
8:30 – 11:30 a.m.

  • #411: Prediction of Clinical Hepatotoxicity of Clinical Drug Candidates using the Novel C-DILI Assay: A Retrospective Case Study – Renato Scialis¹, Jonathan Jackson², Matthew Palmer2, Maggie McMullen², Kenneth R. Brouwer², William G. Humphreys¹ (contributing authors)
    • Affiliations: ¹Preclinical Candidate Optimization, Bristol-Myers Squibb, Princeton, NJ 08540, ²Qualyst Transporter Solutions LLC, a BioIVT company, Durham, NC 27713

This poster describes how the C-DILI Assay was used to determine the hepatotoxicity potential of three Bristol-Myers Squibb clinical candidates.

  • #143: Hepatobiliary Disposition of 15 Non-Therapeutic Chemicals in Sandwich-Culture Rat Hepatocytes using B-CLEAR Technology – Jonathan Jackson2 (contributing author)

This study, which was conducted as part of the EPA’s ToxCast™ Toxicity Forecaster, evaluated the hepatobiliary disposition of select chemicals, including several compounds used in crop protection products.

BioIVT experts will also be available to answer questions about the company’s full range of ADME-toxicology products and services, and to demonstrate the C-DILI Assay, in booth #516.

For more information about this conference, please visit

About BioIVT

BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease-state samples including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit or follow the company on Twitter @BioIVT.

BioIVT Contact: Courtney Noah, Vice President of Marketing, 516-483-1196
Media Contact: Lisa Osborne, Rana Healthcare Solutions, 206-992-5245,